124 related articles for article (PubMed ID: 38828490)
1. Longitudinal patient-reported outcomes on genotype-guided irinotecan dosing: feasibility and clinical relevance.
Sorah JD; Deal AM; Stein SI; Jonsson M; Innocenti F; Turk A; Boles JC; Irvin W; Basch EM; Sanoff HK; Wood WA
Oncologist; 2024 Jun; ():. PubMed ID: 38828490
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
Dueck AC; Scher HI; Bennett AV; Mazza GL; Thanarajasingam G; Schwab G; Weitzman AL; Rogak LJ; Basch E
JAMA Oncol; 2020 Feb; 6(2):e193332. PubMed ID: 31556911
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients.
Baeksted C; Pappot H; Nissen A; Hjollund NH; Mitchell SA; Basch E; Bidstrup PE; Dalton SO; Johansen C
J Patient Rep Outcomes; 2017; 1(1):1. PubMed ID: 29757324
[TBL] [Abstract][Full Text] [Related]
4. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Bruner DW; Hanisch LJ; Reeve BB; Trotti AM; Schrag D; Sit L; Mendoza TR; Minasian L; O'Mara A; Denicoff AM; Rowland JH; Montello M; Geoghegan C; Abernethy AP; Clauser SB; Castro K; Mitchell SA; Burke L; Trentacosti AM; Basch EM
Transl Behav Med; 2011 Mar; 1(1):110-22. PubMed ID: 24073038
[TBL] [Abstract][Full Text] [Related]
5. Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.
McFatrich M; Brondon J; Lucas NR; Hinds PS; Maurer SH; Mack JW; Freyer DR; Jacobs SS; Baker JN; Mowbray C; Wang M; Castellino SM; Barz Leahy A; Reeve BB
Cancer; 2020 Jan; 126(1):140-147. PubMed ID: 31553494
[TBL] [Abstract][Full Text] [Related]
6. Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE
Minasian LM; O'Mara A; Mitchell SA
Patient Relat Outcome Meas; 2022; 13():249-258. PubMed ID: 36524232
[TBL] [Abstract][Full Text] [Related]
7. Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.
Veitch ZW; Shepshelovich D; Gallagher C; Wang L; Abdul Razak AR; Spreafico A; Bedard PL; Siu LL; Minasian L; Hansen AR
J Natl Cancer Inst; 2021 Aug; 113(8):980-988. PubMed ID: 33616650
[TBL] [Abstract][Full Text] [Related]
8. Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events.
Speck RM; Lenderking WR; Shaw JW
J Patient Rep Outcomes; 2017; 2():35. PubMed ID: 30175317
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE.
Watson GA; Veitch ZW; Shepshelovich D; Liu ZA; Spreafico A; Abdul Razak AR; Bedard PL; Siu LL; Minasian L; Hansen AR
Br J Cancer; 2022 Nov; 127(9):1629-1635. PubMed ID: 36008705
[TBL] [Abstract][Full Text] [Related]
10. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Chung AE; Shoenbill K; Mitchell SA; Dueck AC; Schrag D; Bruner DW; Minasian LM; St Germain D; O'Mara AM; Baumgartner P; Rogak LJ; Abernethy AP; Griffin AC; Basch EM
J Am Med Inform Assoc; 2019 Apr; 26(4):276-285. PubMed ID: 30840079
[TBL] [Abstract][Full Text] [Related]
11. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
Basch E; Reeve BB; Mitchell SA; Clauser SB; Minasian LM; Dueck AC; Mendoza TR; Hay J; Atkinson TM; Abernethy AP; Bruner DW; Cleeland CS; Sloan JA; Chilukuri R; Baumgartner P; Denicoff A; St Germain D; O'Mara AM; Chen A; Kelaghan J; Bennett AV; Sit L; Rogak L; Barz A; Paul DB; Schrag D
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25265940
[TBL] [Abstract][Full Text] [Related]
12. Clinicians versus patients subjective adverse events assessment: based on patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
Liu L; Suo T; Shen Y; Geng C; Song Z; Liu F; Wang J; Xie Y; Zhang Y; Tang T; Zhang L; Wang W
Qual Life Res; 2020 Nov; 29(11):3009-3015. PubMed ID: 32564293
[TBL] [Abstract][Full Text] [Related]
13. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review.
Atkinson TM; Ryan SJ; Bennett AV; Stover AM; Saracino RM; Rogak LJ; Jewell ST; Matsoukas K; Li Y; Basch E
Support Care Cancer; 2016 Aug; 24(8):3669-76. PubMed ID: 27260018
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported Adverse Events During Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501).
Snyder RA; Dueck AC; Fruth B; Shi Q; Hubbard JM; Herman JM; O'Reilly EM; Katz MHG
Ann Surg; 2023 Oct; 278(4):598-608. PubMed ID: 37334719
[TBL] [Abstract][Full Text] [Related]
15. Validity and Reliability of the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events.
Reeve BB; McFatrich M; Mack JW; Maurer SH; Jacobs SS; Freyer DR; Withycombe JS; Baker JN; Castellino SM; Lin L; Lucas NR; Hinds PS
J Natl Cancer Inst; 2020 Nov; 112(11):1143-1152. PubMed ID: 31999349
[TBL] [Abstract][Full Text] [Related]
16. The Japanese version of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events.
Kawaguchi T; Azuma K; Sano M; Kim S; Kawahara Y; Sano Y; Shimodaira T; Ishibashi K; Miyaji T; Basch E; Yamaguchi T
J Patient Rep Outcomes; 2017; 2(1):2. PubMed ID: 29757309
[TBL] [Abstract][Full Text] [Related]
17. A study demonstrating users' preference for the adapted-REQUITE patient-reported outcome questionnaire over PRO-CTCAE
Jordan T; Nuamek T; Fornacon-Wood I; Califano R; Coote J; Harris M; Mistry H; Taylor P; Woolf D; Faivre-Finn C
Front Oncol; 2024; 14():1328871. PubMed ID: 38660130
[TBL] [Abstract][Full Text] [Related]
18. Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative.
Reeve BB; McFatrich M; Pinheiro LC; Weaver MS; Sung L; Withycombe JS; Baker JN; Mack JW; Waldron MK; Gibson D; Tomlinson D; Freyer DR; Mowbray C; Jacobs S; Palma D; Martens CE; Gold SH; Jackson KD; Hinds PS
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27650708
[TBL] [Abstract][Full Text] [Related]
19. Evaluating Treatment Tolerability Using the Toxicity Index With Patient-Reported Outcomes Data.
Langlais B; Mazza GL; Thanarajasingam G; Rogak LJ; Ginos B; Heon N; Scher HI; Schwab G; Ganz PA; Basch E; Dueck AC
J Pain Symptom Manage; 2022 Feb; 63(2):311-320. PubMed ID: 34371138
[TBL] [Abstract][Full Text] [Related]
20. Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study.
Yeung AR; Pugh SL; Klopp AH; Gil KM; Wenzel L; Westin SN; Gaffney DK; Small W; Thompson S; Doncals DE; Cantuaria GHC; Yaremko BP; Chang A; Kundapur V; Mohan DS; Haas ML; Kim YB; Ferguson CL; Deshmukh S; Bruner DW; Kachnic LA
J Clin Oncol; 2020 May; 38(15):1685-1692. PubMed ID: 32073955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
